Evaluation of inhibitory drug interactions during drug development: genetic polymorphisms must be considered.
Lee
Lois S
LS
Clinical Pharmacology Research Center, The Research Institute, Bassett Healthcare, USA.
Nafziger
Anne N
AN
Bertino
Joseph S
JS
D001189:Aryl Hydrocarbon Hydroxylases / Q000187:drug effects / Q000235:genetics / Q000378:metabolism; D002986:Clinical Trials as Topic / Q000379:methods / Q000639:trends*; D065731:Cytochrome P-450 CYP2C19; D019389:Cytochrome P-450 CYP2D6 / Q000187:drug effects / Q000235:genetics / Q000378:metabolism; D004353:Drug Evaluation, Preclinical / Q000379:methods / Q000639:trends*; D004347:Drug Interactions; D006801:Humans; D006899:Mixed Function Oxygenases / Q000187:drug effects / Q000235:genetics / Q000378:metabolism; D011110:Polymorphism, Genetic / Q000187:drug effects* / Q000502:physiology*; D013678:Technology, Pharmaceutical / Q000379:methods / Q000639:trends*
D006899:Mixed Function Oxygenases; D001189:Aryl Hydrocarbon Hydroxylases; C045793:CYP2C19 protein, human; D065731:Cytochrome P-450 CYP2C19; D019389:Cytochrome P-450 CYP2D6